Literature DB >> 23852707

Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex.

Darcy A Krueger1.   

Abstract

OPINION STATEMENT: Historically, before the advent of modern imaging and genetic testing, Tuberous Sclerosis Complex (TSC) was more of a diagnostic challenge and less of a treatment challenge. This is because the natural history of TSC was poorly understood and TSC-specific treatments were non-existent. In the current era, diagnosis is more straightforward but management is much more complex. Disease manifestations vary by age, severity, and organ system. Management issues in the first few months of life, including neurologic manifestations, are very different than late childhood, adolescence, and adulthood. With increasing numbers of TSC diagnoses being made prenatally or shortly after birth, the opportunity for interventions that may improve long-term developmental and epilepsy outcomes now may precede the onset of neurological clinical symptoms. Familiarity and anticipation of these neurologic complications and rapid response to their emergence is crucial. Periodic imaging surveillance for development of subependymal giant cell astrocytoma (SEGA), preferably by magnetic resonance imaging (MRI) every 1-3 years, is now standard of care. Early SEGA detection provides opportunity to initiate pharmacologic treatment with everolimus if appropriate, thereby negating the need for invasive surgery. Routine electroencephalography (EEG) in asymptomatic infants for the first year or two of life is becoming increasingly accepted, with treatment initiation of vigabatrin dependent on concerning EEG findings instead of waiting until onset of clinical seizures, the traditional approach. Effective SEGA treatment and optimal seizure control remain principal during the first few decades of life for the clinical neurologist involved in the management of TSC. However, during the same period and extending through adulthood, assessment of TSC-associated neuropsychiatric disorder (TAND) is also key to the best clinical outcome and quality of life for affected individuals and their surrounding family and caregivers.

Entities:  

Year:  2013        PMID: 23852707     DOI: 10.1007/s11940-013-0249-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  69 in total

1.  Brain tumors in tuberous sclerosis. A clinicopathologic study of the Mayo Clinic experience.

Authors:  C W Shepherd; B Scheithauer; M R Gomez
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

Review 2.  Neonatal subependymal giant cell astrocytoma: new case and review of literature.

Authors:  G Praveen Raju; David K Urion; Mustafa Sahin
Journal:  Pediatr Neurol       Date:  2007-02       Impact factor: 3.372

3.  Rheb binds and regulates the mTOR kinase.

Authors:  Xiaomeng Long; Yenshou Lin; Sara Ortiz-Vega; Kazuyoshi Yonezawa; Joseph Avruch
Journal:  Curr Biol       Date:  2005-04-26       Impact factor: 10.834

4.  Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.

Authors:  Darcy A Krueger; Marguerite M Care; Karen Agricola; Cindy Tudor; Maxwell Mays; David Neal Franz
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

5.  Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.

Authors:  Peter Kinirons; Gianpiero L Cavalleri; Dierdre O'Rourke; Colin P Doherty; Irene Reid; Patricia Logan; Brenda Liggan; Norman Delanty
Journal:  Epilepsia       Date:  2006-02       Impact factor: 5.864

6.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

Review 7.  Nursing implications for the lifelong management of tuberous sclerosis complex.

Authors:  Karen Agricola; Cindy Tudor; Darcy Krueger; David Neal Franz
Journal:  J Neurosci Nurs       Date:  2013-08       Impact factor: 1.230

8.  Identification and characterization of the tuberous sclerosis gene on chromosome 16.

Authors: 
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

9.  Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial.

Authors:  James J Collins; Cynthia Tudor; Jennifer M Leonard; Gail Chuck; David Neal Franz
Journal:  J Child Neurol       Date:  2006-01       Impact factor: 1.987

10.  Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.

Authors:  Mary Kay Koenig; Adelaide A Hebert; Joan Roberson; Joshua Samuels; John Slopis; Audrey Woerner; Hope Northrup
Journal:  Drugs R D       Date:  2012-09-01
View more
  12 in total

1.  A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.

Authors:  Daniel J Ma; Evanthia Galanis; S Keith Anderson; David Schiff; Timothy J Kaufmann; Patrick J Peller; Caterina Giannini; Paul D Brown; Joon H Uhm; Steven McGraw; Kurt A Jaeckle; Patrick J Flynn; Keith L Ligon; Jan C Buckner; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2014-12-18       Impact factor: 12.300

Review 2.  Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.

Authors:  Joshua A Samuels
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-16       Impact factor: 8.237

3.  Epilepsy in Children with Tuberous Sclerosis Complex: A Prospective Observational Study in Bangladesh.

Authors:  Md Mizanur Rahman; Kanij Fatema
Journal:  J Epilepsy Res       Date:  2020-06-30

Review 4.  Familial syndromes associated with intracranial tumours: a review.

Authors:  Adrianna M Ranger; Yatri K Patel; Navjot Chaudhary; Ram V Anantha
Journal:  Childs Nerv Syst       Date:  2013-11-06       Impact factor: 1.475

Review 5.  Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy.

Authors:  Jamie K Capal; David Neal Franz
Journal:  Neuropsychiatr Dis Treat       Date:  2016-08-25       Impact factor: 2.570

6.  Ketogenic Diet for the Management of Epilepsy Associated with Tuberous Sclerosis Complex in Children.

Authors:  Soyoung Park; Eun Joo Lee; Soyong Eom; Hoon-Chul Kang; Joon Soo Lee; Heung Dong Kim
Journal:  J Epilepsy Res       Date:  2017-06-30

Review 7.  mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.

Authors:  David N Franz; Jamie K Capal
Journal:  Orphanet J Rare Dis       Date:  2017-03-14       Impact factor: 4.123

8.  Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study.

Authors:  Rima Nabbout; Elena Belousova; Mirjana P Benedik; Tom Carter; Vincent Cottin; Paolo Curatolo; Maria Dahlin; Lisa D Amato; Guillaume Beaure d'Augères; Petrus J de Vries; José C Ferreira; Martha Feucht; Carla Fladrowski; Christoph Hertzberg; Sergiusz Jozwiak; John A Lawson; Alfons Macaya; Ruben Marques; Finbar O'Callaghan; Jiong Qin; Valentin Sander; Matthias Sauter; Seema Shah; Yukitoshi Takahashi; Renaud Touraine; Sotiris Youroukos; Bernard Zonnenberg; Anna Jansen; John C Kingswood
Journal:  Epilepsia Open       Date:  2018-12-21

9.  Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy.

Authors:  James W Wheless
Journal:  Epilepsy Behav Case Rep       Date:  2015-08-12

10.  Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex.

Authors:  Susanne Brakemeier; Lars Vogt; Lisa C Adams; Bianca Zukunft; Gerd Diederichs; Bernd Hamm; Klemens Budde; Kai-Uwe Eckardt; Marcus R Makowski
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.